ReviewImmunity & ageing : I & A2023
Targeting the hallmarks of aging to improve influenza vaccine responses in older adults.
Review in Immunity & ageing : I & A, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 24 citations in OpenAlex.
- Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation study.Human vaccines & immunotherapeutics · 2026Trial
- Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Trial
- Article
- Evaluation of Safety and Immunogenicity of High-Dose Quadrivalent Seasonal Influenza Split Vaccine: A Preclinical Study.Vaccines · 2026Article
- Pre-existing influenza antibodies, younger age, and increased CD4 THuman immunology · 2026Article
- Respiratory virus immune response in the aged host.Immunity & ageing : I & A · 2026Review
- Distribution and function of human long-lasting T cells in aging and non-small cell lung cancer.Frontiers in immunology · 2026Review
- From neuraminidase inhibitors to novel mechanisms: expanding therapeutic strategies against influenza.Frontiers in cellular and infection microbiology · 2026Review
- Korea 2024-2025 Influenza and Respiratory Virus Laboratory Surveillance Report.Public health weekly report · 2026Article
- Lactate Secretion by Monocytes as a Determinant of Innate Immune Cell Fitness in Healthy Elderly.Aging cell · 2025Article
- [Seasonal Influenza Virus Activity during the 2024-2025 Season: Based on the Republic of Korea's National Pathogen Surveillance Data].Jugan geon-gang gwa jilbyeong · 2025Article
- Immunosenescence: signaling pathways, diseases and therapeutic targets.Signal transduction and targeted therapy · 2025Review
- Understanding and improving vaccine efficacy in older adults.Nature aging · 2025Review
- Age-Related Impairment of Innate and Adaptive Immune Responses Exacerbates Herpes Simplex Viral Infection.Pathogens (Basel, Switzerland) · 2025Article
- Observational
- HEALTHY AGING: THE PROMISE, AND PERILS, OF GEROSCIENCE.Transactions of the American Clinical and Climatological Association · 2025Review
- Multifaceted virus-like particles: Navigating towards broadly effective influenza A virus vaccines.Current research in microbial sciences · 2025Review
- Molecular and Cellular Mechanisms of Immunosenescence: Modulation Through Interventions and Lifestyle Changes.Biology · 2024Review
- Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications.Signal transduction and targeted therapy · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Age-related declines in immune response pose a challenge in combating diseases later in life. Influenza (flu) infection remains a significant burden on older populations and often results in catastrophic disability in those who survive infection. Despite having vaccines designed specifically for older adults, the burden of flu remains high and overall flu vaccine efficacy remains inadequate in this population. Recent geroscience research has highlighted the utility in targeting biological aging to improve multiple age-related declines. Indeed, the response to vaccination is highly coordinated, and diminished responses in older adults are likely not due to a singular deficit, but rather a multitude of age-related declines. In this review we highlight deficits in the aged vaccine responses and potential geroscience guided approaches to overcome these deficits. More specifically, we propose that alternative vaccine platforms and interventions that target the hallmarks of aging, including inflammation, cellular senescence, microbiome disturbances, and mitochondrial dysfunction, may improve vaccine responses and overall immunological resilience in older adults. Elucidating novel interventions and approaches that enhance immunological protection from vaccination is crucial to minimize the disproportionate effect of flu and other infectious diseases on older adults.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.